CEBPBas a potential biomarker for prognosis and immune infiltration in clear cell renal cell carcinoma

Abstract

AbstractClear cell renal cell carcinoma (ccRCC) is an aggressive kidney cancer subtype with poor prognosis.This study explores the expression and clinical significance of the CCAAT/enhancer-binding protein betaCEBPBgene in ccRCC. RNA sequencing, gene amplification, and mutation data were sourced from TCGA, UCSC XENA, and cBioPortal. Data processing involved the STAR workflow and R software for statistical analysis and visualization. Experimental validation used immunohistochemistry and RT-qPCR on 58 patient tissue samples. Functional pathway enrichment was performed using GO-KEGG and GSEA analyses, and PPI networks were constructed with STRING and Cytoscape. Immune infiltration and survival analyses were conducted using Spearman correlation and Cox regression models.Results showed significantly higherCEBPBexpression in ccRCC tissues compared to adjacent normal tissues. Clinical variable grouping indicated significant differences inCEBPBexpression. Enrichment analyses identified involvement in complement and coagulation cascades and carbon metabolism. PPI networks highlighted strong interactions with STAT3 and EP300. Immune infiltration analysis revealed significant correlations with multiple immune cell types. HighCEBPBexpression was linked to poor prognosis and demonstrated high diagnostic accuracy for ccRCC.Author summaryKidney Renal Clear Cell Carcinoma (KIRC) is a major subtype of renal cancer with significant clinical implications. This study investigates the role ofCEBPB, a transcription factor, in KIRC using RNA sequencing data from TCGA and GTEx databases. We analyzedCEBPBexpression, mutation status, and its correlation with clinical features and immune infiltration. Our findings reveal elevatedCEBPBexpression in tumor tissues, significantly associated with advanced T, N, M stages and poor overall survival. Functional analyses indicate thatCEBPBinteracts with key proteins and pathways involved in tumorigenesis. Additionally, highCEBPBexpression correlates with increased immune cell infiltration, suggesting its role in tumor-immune interactions. This research highlightsCEBPBas a potential prognostic biomarker and therapeutic target in KIRC, offering new insights for clinical management and treatment strategies.